Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease
James Evans, Meenakshi Malhotra, John F. Cryan, et al.
British Journal of Pharmacology (2016) Vol. 173, Iss. 21, pp. 3041-3079
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports
Maike J.M. Uijen, Yvonne H. W. Derks, Robin Merkx, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 13, pp. 4350-4368
Open Access | Times Cited: 106
Glu-Ureido–Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
Klaus Kopka, Martina Benešová, Cyril Bařinka, et al.
Journal of Nuclear Medicine (2017) Vol. 58, Iss. Supplement 2, pp. 17S-26S
Open Access | Times Cited: 144
Fluorescence Detection of Prostate Cancer by an Activatable Fluorescence Probe for PSMA Carboxypeptidase Activity
Minoru Kawatani, Kyoko Yamamoto, Daisuke Yamada, et al.
Journal of the American Chemical Society (2019) Vol. 141, Iss. 26, pp. 10409-10416
Closed Access | Times Cited: 84
Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
Asta Juzeniene, Vilde Yuli Stenberg, Øyvind S. Bruland, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 779-779
Open Access | Times Cited: 69
Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases
Mariz Kasoha, C. Unger, Erich‐Franz Solomayer, et al.
Clinical & Experimental Metastasis (2017) Vol. 34, Iss. 8, pp. 479-490
Closed Access | Times Cited: 71
Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer
Sumith A. Kularatne, Mini Thomas, Carrie Myers, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 1, pp. 177-187
Open Access | Times Cited: 66
Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging
Heying Duan, Andrei Iagaru, Carina Marí Aparici
Nanotheranostics (2021) Vol. 6, Iss. 1, pp. 103-117
Open Access | Times Cited: 45
Effects of Linker Modification on Tumor-to-Kidney Contrast of 68Ga-Labeled PSMA-Targeted Imaging Probes
Hsiou‐Ting Kuo, Jinhe Pan, Zhengxing Zhang, et al.
Molecular Pharmaceutics (2018) Vol. 15, Iss. 8, pp. 3502-3511
Closed Access | Times Cited: 55
Advances in targeted alpha therapy for prostate cancer
Giuseppe De Vincentis, W.R. Gerritsen, Jürgen E. Gschwend, et al.
Annals of Oncology (2019) Vol. 30, Iss. 11, pp. 1728-1739
Open Access | Times Cited: 53
Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue
Lindsey A. Vandergrift, Emily A. Decelle, Johannes Kurth, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 51
PSMA expression on neovasculature of solid tumors.

Histology and histopathology (2020) Vol. 35, Iss. 9, pp. 919-927
Closed Access | Times Cited: 47
Urea-based anticancer agents. Exploring 100-years of research with an eye to the future
Roberta Listro, Giacomo Rossino, Federica Piaggi, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 27
PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome
Martina Sollini, Luca Di Tommaso, Margarita Kirienko, et al.
EJNMMI Research (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 43
PSMA-Targeted Mesoporous Silica Nanoparticles for Selective Intracellular Delivery of Docetaxel in Prostate Cancer Cells
Eva Rivero‐Buceta, Carla Vidaurre-Agut, C.D. Vera Donoso, et al.
ACS Omega (2019) Vol. 4, Iss. 1, pp. 1281-1291
Open Access | Times Cited: 41
Electrostatic Effects Accelerate Decatungstate-Catalyzed C–H Fluorination Using [18F]- and [19F]NFSI in Small Molecules and Peptide Mimics
Zheliang Yuan, Hua Yang, Noeen Malik, et al.
ACS Catalysis (2019) Vol. 9, Iss. 9, pp. 8276-8284
Closed Access | Times Cited: 41
PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review
Christophe Van de Wiele, Mike Sathekge, Bart De Spiegeleer, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 19, pp. 4886-4886
Open Access | Times Cited: 40
High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
Tadashi Watabe, Motohide Uemura, Fumihiko Soeda, et al.
Annals of Nuclear Medicine (2021) Vol. 35, Iss. 4, pp. 523-528
Open Access | Times Cited: 32
The Role of PET Imaging in the Differential Diagnosis between Radiation Necrosis and Recurrent Disease in Irradiated Adult-Type Diffuse Gliomas: A Systematic Review
Gaia Ninatti, Cristiano Pini, Fabrizia Gelardi, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 364-364
Open Access | Times Cited: 13
Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy
Mingze He, Yu Cao, Changliang Chi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Parallel Metabolomics and Lipidomics of a PSMA/GCPII Deficient Mouse Model Reveal Alteration of NAAG Levels and Brain Lipid Composition
František Sedlák, Aleš Kvasnička, Barbora Marešová, et al.
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 7, pp. 1342-1355
Open Access | Times Cited: 4
Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer
Haibo Xi, Gongxian Wang, Bin Fu, et al.
Biological and Pharmaceutical Bulletin (2015) Vol. 38, Iss. 6, pp. 827-835
Open Access | Times Cited: 36
The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia
Ian Alberts, Christos Sachpekidis, Lotte Dijkstra, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2019) Vol. 47, Iss. 3, pp. 642-651
Closed Access | Times Cited: 34
Nanoparticles Yield Increased Drug Uptake and Therapeutic Efficacy upon Sequential Near-Infrared Irradiation
Dong Luo, Xinning Wang, Ethan Walker, et al.
ACS Nano (2020) Vol. 14, Iss. 11, pp. 15193-15203
Open Access | Times Cited: 30
Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance
Silvia Valtorta, Daniela Salvatore, Paolo Rainone, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 16, pp. 5631-5631
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top